Pulmonology

Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

Ensifentrine, a PDE3 and 4 inhibitor from Verona Pharma, was associated with significantly improved lung function and reduced COPD exacerbations over 24 weeks.

Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.

A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.

Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.

The FDA provided 510(k) clearance for the COR-12 wireless ECG device, which was now integrated with the SpiroSphere.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

This review of May 2024 covered several notable topics in the pulmonary health field, including research into vaping, lung abnormalities, and treatment of COPD.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.

This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as symptoms.

These data suggest vaping poses potential threats to the development of the brain and organs, with teenagers being a predominant target due to surges in use.

A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

In this Q&A, Kathuria explains the current state of smoking cessation programs and how health care providers can help patients combat their tobacco dependence.

In the latest Lungcast, Drs. McCurry and Valapour answered several questions on the candidacy of post-infectious COVID-19 patients for lung transplantation and on long COVID.

During this segment of Lungcast, Valapour and McCurry discussed recent changes made to lung allocation scores as well as the topic of graft rejection.

AHN's AI-ILD clinic provides collaborative care, uniting pulmonology and rheumatology specialists for efficient treatment of ILD.

In this Month in Review article for March, news on topics such as asthma and the impacts of pollution in the pulmonology field were highlighted.

These data may have impactful clinical and health policy implications, given that hospitalizations for CAP are known to be common and given the frequency of incorrect diagnoses.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.

The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.